Vaccine compositions comprising an attenuated mutant Zika virus
US10849943B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 22, 2017 |
| Grant date | Dec 1, 2020 |
| Priority date | — |
| Expiry date | Aug 1, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.